Prostate Cancer Coverage from Every Angle

David P. Dearnaley, MD, on Helping Patients Tolerate Radiation Therapies for Prostate Cancer

Posted: Wednesday, February 19, 2020

David P. Dearnaley, MD, of The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, discusses his observations on toxicities associated with hypofractionated high-dose intensity modulated radiotherapy, and ways to help mitigate side effects.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.